HPV-based Testing And Treatment For The Elimination Of Cervical Cancer In Papua New Guinea (HPVTATE)
Funder
National Health and Medical Research Council
Funding Amount
$1,590,166.00
Summary
Building on the innovative cervical screening model that we successfully designed and delivered in partnership with provincial health authorities in urban primary care settings in PNG, the overarching aim of the proposed study is to determine the reach, effectiveness, cost-effectiveness, acceptability and scalability of HPV-based testing and treatment for the elimination of cervical cancer (HPVTATE) among women in rural and remote communities in Papua New Guinea.
Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
The Population Impact Of Human Papillomavirus Vaccination On Circulating Genotypes
Funder
National Health and Medical Research Council
Funding Amount
$249,259.00
Summary
Infection with human papillomavirus (HPV) is very common. Persistent infection can cause abnormal changes to cervical cells as found on Pap smears and if untreated, over time can develop into cervical cancer. Recently, a vaccine was introduced in Australia for women aged 12-26. To monitor the effectiveness of this vaccine, young women aged 18-22 will be asked to self-collect a sample for HPV detection which will determine if HPV types targeted by vaccine are reducing in prevalence.
Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Optimising Cervical Screening After The Introduction Of HPV Vaccination In Australia: Modelling Of Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$316,089.00
Summary
This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer ....This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer simulation methods. HPV is the virus responsible for the development of cervical cancer, and clinical trials have demonstrated that HPV vaccines administered to adoloescent girls are very effective at preventing disease that might have led to cancer in the future. However, Australia currently has a very effective Pap smear screening program, and in the first phase after the introduction of vaccination it will be important for women to continue being screened as usual. In the long term, HPV vaccination is expected to reduce the need for Pap smears. The research will involve a very detailed simulation of how HPV is transmitted in the Australian population, and how this will change after vaccination. The simulation will address questions of importance for any future public HPV vaccination program, such as whether males should be vaccinated as well as females. The simulation will also be used to determine the optimal starting age and frequency of Pap smears in the future. The outcomes of the research will be very important for policy-makers. In the long term, this research will ensure that the best recommendations are formulated for the timing and frequency of Pap smears after HPV vaccination is introduced.Read moreRead less
Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Evaluation Of Future Cervical Cancer Prevention Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
The overall aim of the project is to use simulation modelling to perform a detailed epidemiologic and economic evaluation of the role of primary HPV DNA testing in Australia in the context of HPV vaccination. The project involves a collaboration with investigators at the National Cancer Institute USA, to analyse data from large studies conducted around the world and to build an accurate simulation of HPV infection and the development of cervical cancer.
Evaluation Of Primary HPV Testing For Cervical Screening In Australia
Funder
National Health and Medical Research Council
Funding Amount
$701,037.00
Summary
The overall aim of the project is to use simulation modelling to perform a detailed evaluation of new approaches to cervical screening in Australia, taking into account the implementation of the National HPV Vaccination Program. The project involves collaboration between Australian researchers and investigators at the National Cancer Institute USA. We will integrate local and international data to lead the world in understanding how cervical screening should best be performed in the context of H ....The overall aim of the project is to use simulation modelling to perform a detailed evaluation of new approaches to cervical screening in Australia, taking into account the implementation of the National HPV Vaccination Program. The project involves collaboration between Australian researchers and investigators at the National Cancer Institute USA. We will integrate local and international data to lead the world in understanding how cervical screening should best be performed in the context of HPV vaccination.Read moreRead less
Perinatal Outcomes Following Treatment For Cervical Dysplasia
Funder
National Health and Medical Research Council
Funding Amount
$98,600.00
Summary
A very high proportion of women in Australia have regular cervical screening ('pap' tests) for early detection of any early abnormal changes of the cervix. Women with abnormalities are referred for further investigation and some go on to have the areas with abnormalities treated either by surgical removal of small amounts of tissue or by other heat or laser treatments of affected areas. Many women having these treatments are of child-bearing age and may not have had children, or may seek to have ....A very high proportion of women in Australia have regular cervical screening ('pap' tests) for early detection of any early abnormal changes of the cervix. Women with abnormalities are referred for further investigation and some go on to have the areas with abnormalities treated either by surgical removal of small amounts of tissue or by other heat or laser treatments of affected areas. Many women having these treatments are of child-bearing age and may not have had children, or may seek to have more children after treatment. There are unanswered questions about the extent to which any or all of these treatments might, by changes to the cervix, lead to preterm birth in any subsequent pregnancy. In the proposed study, records relating to women referred from 1982 to 2000 for assessment and possible treatment of cervical abnormalities at a major hospital will be linked to Victorian birth records from 1983 to 2001. This will allow a comparison of preterm birth in the group of women referred with cervical abnormalities, with preterm births in the Victorian population, and comparing women who do and don't have treatment, taking into account other important factors such as the mother's age, and her previous pregnancies. The information will be of value to women themselves, to gynaecologists and to screening services.Read moreRead less